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1. Introduction 
During the past ten years, the molecular mecha- 
nisms by which several antibiotics or drugs interfere 
with cell metabolism have been elucidated. Since 
then, a new era in research started when it became 
evident that many of these inhibitors can be used as 
highly specific reagents for blocking complex cellu- 
lar processes uch as the synthesis of cell wall con- 
stituents, the synthesis of nucleic acids and proteins, 
biological oxidations, ion transport across mem- 
branes and gluconeogenesis. These topics have been 
discussed extensively in 1969 at Madrid [ 1,2], Mos- 
bath [3] tid Tokyo [4], and in 1970 at Washing- 
ton [5] and Riga [review 61. From recent advances 
in this field, a few which in the author’s view are 
the most impressive examples have been selected to 
show the contribution of this research to solving pro- 
blems on the structure and function of nucleic acids 
and ribosomes. 
2. Nucleic acids 
2.1.DNA 
Actinomycin (I)* is probably the best and most 
thorougly studied antibiotic which has been shown 
to alter the structure and function of DNA. Hamilton 
* The numbers identify the structures in the Appendix to 
this Review letter. 
et al. [7] proposed a model in which actinomycin 
is bound in the minor groove and the purine 2- 
amino-group of deoxyguanosine is required for 
actinomycin binding to native DNA. Miiller and 
Crothers [8] suggested from their results a hydro- 
gen-bonded model in which the chromophore of 
actinomycin intercalates between adjacent base 
pairs with the peptide rings at the outside of the 
DNA double helix. Wells and Larson [9] have now 
studied the binding of actinomycin to 17 different 
synthetic DNA polymers by a variety of techniques 
including equilibrium dialysis, in vitro transcription 
and analytical buoyant density centrifugation. The 
results of these experiments can be briefly summa- 
rized: The presence of deoxyguanosine is not ne- 
cessary for the binding of actinomycin to all kinds 
of DNA, since poly d1 binds actinomycin almost as 
tightly as does native DNA; the presence of deoxy- 
guanosine is not ,suffcient for binding since poly 
d(A-T-C) . poly d(G-A-T) which contains 33% 
G + C binds virtually no actinomycin. A marked 
nucleotide sequence preference exists for the bind- 
ing reaction. By comparing the binding capacity of 
sequence isomeric DNAs, the isomer which contains 
both purines and pyrimidines on both complemen- 
tary strands, binds more actinomycin and binds it 
more tightly than the isomer containing all purines 
in one strand and the pyrimidines in the comple- 
mentary strand. These findings strongly suggest 
that the apparent specificity of guanine for actino- 
mycin binding to DNA must be a secondary effect 
North-Holland Ptrblishing Company - Amsterdam 261 
and caused by an influence of this base on a certain by antibiotics or drugs only favour the intercalation 
steric and electronic environment. Most important model of Lerman, but do not prove it. 
for actinomycin association with DNA is the pres- Bauer and Vinograd [ 131 studied the binding iso- 
ence of a suitable DNA configuration. The results therms of ethidium bromide to closed circular and 
are not consistent with the model of Hamilton et nicked circular DNA of the phage SV 40. From the 
al. but favour the hydrogen-bonded intercalation binding isotherms the free energy of superhelix for- 
model of Miiller and Crothers. mation of SV 40 closed DNA at 25” in 5.8 M CsCl 
Ethidium bromide (II), daunomycin (III), nogala- could be calculated. The differences in the binding 
mycin (IV), chromomycin (V) and mithramycin (VI): isotherms observed for the two SV 40 DNAs are a 
That actinomycin is partially intercalated between result of the additional free energy required for 
adjacent base pairs of the DNA double helix is also superhelix formation in the closed molecule. 
suggested by Waring, who compared several DNA Ethidium bromide is an effective mutagen causing 
complexing antibiotics with respect to their influence respiratory deficiency in yeast. Normally, this mu- 
on supercoiled circular DNA. Intercalation of a dye tation occurs spontaneously at an unusually high 
between adjacent base pairs of the double helix of frequency of approx. 1% per generation. This mu- 
DNA requires that the helix becomes partially un- tation is carried by a cytoplasmic factor, p, generally 
coiled at the point of insertion of a dye molecule assumed to be mitochondrial DNA, missing in the 
between the base pairs. This proposed uncoiling has petite phenotype @-). Slonimski et al. [14] could 
been shown experimentally by Crawford and Waring convert a respiratory sufficient culture to more than 
[lo] . Circular duplex DNA @x 174 displays large 98%,petites within 3.2 cell doublings by the use of 
changes in supercoiling in response to a local un- .ethidium. This system allows the study of the mole- 
coiling upon insertion of a dye molecule. During cular events associated with the conversion of normal 
the first phase of drug binding, the number of right- to petite cells. Goldring et al. [ 151 studied the pro- 
handed supercoils originally present in the circle perties of mitochondrial DNA at various times 
decreases. At a critical level of binding, the super- during the mutation process and observed that ethi- 
coils are just removed so that the DNA molecules dium bromide alters the synthesis of DNA and RNA 
behave as untwisted open circles. As further drug in mitochondria without affecting extramitochondrial 
binding takes place, left-handed supercoils appear. nucleic acid synthesis; mitochondrial DNA synthesis 
Since supercoiled circles are more compact than the is preferentially inhibited. Pre-existing mitochondrial 
equivalent open circles, they sediment more rapidly. DNA is progressively degraded. The authors suggest 
Therefore, the loss and reappearance of supercoils that supercoiled molecules of mitochondrial DNA 
can be easily observed by the changes in sedimentation exist and are distorted upon insertion of the dye, 
coefficients. By using this technique it could be leading to an increased nuclease attack which accounts 
demonstrated that, like ethidium bromide, actino- for the degradation. The degradation products might 
mycin, daunomycin and nogalamycin cause uncoiling be replicated, but are no longer able to be transcribed 
of the helix whereas chromomycin and mithramycin and translated to produce functional gene products. 
do not affect the supercoils [l l] . It was concluded In petites formed by prolonged treatment, no mito- 
that chromomycin and mithramycin do not bind by chondrial DNA could be detected. Zylber et al. [ 16, 
intercalation as had been proposed from earlier physico- 171 also observed that ethidium bromide alters the 
chemical binding studies [ 121. Among several drugs synthesis of DNA and RNA in mitochondria without 
which are believed to interact with DNA by mechanisms affecting extramitochondrial nucleic acid synthesis. 
other than intercalation one exception. was found, To explain the preferential effect of ethidium 
irehdiamine A (VII), which caused uncoiling of the bromide on mitochondrial DNA, it is assumed that 
double helix. Thus uncoiling of the double helix at low concentrations the drug preferentially binds 
might occur also by non-intercalative processes. Like to mitochondrial DNA because this can exist in a 
several other psysicochemical measurements the varia- supercoiled form. However, the size and structure 
tion of the supercoils in closed circular DNA induced of yeast mitochondrial DNA is not yet established. 
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Hollenberg et al. [ 181 showed closed circular mole- 
cules, 25-27 pm long, in Marmur’s laboratory linear 
mitochondrial DNA molecules of two different sizes, 
25-28 pm long and 50-55 pm long, were isolated. 
2.2. tRNA 
Ethidium bromide has also proved to be valuable in 
studying the structure of tRNA. Phenylalanine speci- 
tic tRNAs of yeast, wheat and rat liver have in com- 
mon a fluorescent base called “Y” adjacent to the 
anticodon loop. Low concentrations of the dye show 
a strong binding site for tRNAPhe which only binds 
one ethidium bromide per RNA molecule [ 19,201. 
Assuming that the drug binds by intercalation, the 
bound dye probably remains on the macromolecule 
within the lifetime of the fluorescent state and possi- 
bly has a fKed orientation with respect to the macro- 
molecule. The visible absorption of ethidium bromide 
overlaps with the emission of the “Y” base. There- 
fore, it can act as an energy-acceptor and cause 
quenching of the fluorescence of the “Y” base. The 
amount of quenching depends on the distance 
between the energy donor and acceptor. Fluorescence 
quenching of the “Y” base by ethidium bromide is 
greatly depressed in the presence of Mg’+-indicating 
that the conformation of tRNA is drastically changed 
by Mg*+ so that the distance between the binding 
site for ethidium bromide and the location of the 
base increases considerably. These results clearly 
show an effect of Mg*+ on the tertiary structure of 
tRNA. 
3. RNA-polymerase 
3.1. Bacterial enzyme 
In the RNA-polymerase reaction, several sequen- 
tial processes are involved: (1) association of the DNA 
template with the enzyme, (2) stabilization of the 
complex of enzyme and DNA by the nucleotide 
which forms the 5’-terminus of the RNA chain, (3) 
initiation of the chain, by formation of the first 5’-3’ 
linkage, (4) chain elongation, (5) liberation of the 
synthesized polyribonucleotide chain from the tem- 
plate. 
Rijiipicin (VIII) which specifically inhibits 
bacterial RNA-polymerases, has recently been used 
as a tool to discriminate sigma specific and unspeci- 
fit active complexes of RNA-polymerase and tem- 
plate [21]. The primary effect of rifampicin is the 
inhibition of the association of the DNA template 
with the polymerase. Once this complex is formed, 
the further steps of RNA synthesis in bacterial sys- 
tems are insensitive to rifampicin; chain-initiation, 
formation of the first phosphodiester bond and chain 
elongation can occur in the presence of the inhibitor. 
However, the instability of the binary complex 
between RNA polymerase and template causes a 
residual inhibition of the RNA polymerase reaction 
by rifampicin. 
The complex between RNA-polymerase and tem- 
plates which lack sigma specific initiation sites, poly 
d(AT) or salmon-sperm DNA, are more stable than 
those which are formed when sigma specific tem- 
plates, such as T2 DNA, are used. The less stable com- 
plexes lose their resistance to rifampicin rather rapid- 
ly. The stable complexes between RNA-polymerase 
and sigma unspecific templates lose their resistance 
much more slowly. This now allows one to distin- 
guish sigma specific and unspecific complexes of 
RNA-polymerases and DNA templates. 
3.2. Eucaryo tic enzyme 
cr-Amanitin (IX), a toxic peptide, has been used to 
discriminate between two different types of mamma- 
lian RNA-polymerases [22]. It was suggested that 
RNA polymerase from isolated nuclei contains two 
types of enzyme, one which appears to synthesize 
mainly ribosomal RNA and accumulates in the nucleoli 
and another responsible for the synthesis of DNA- 
like RNA. This latter activity was found to be mainly 
extranucleolar. The two types of RNA-polymerases 
show different sensitivities to o-amanitin. The en- 
zyme preparation of whole nuclei and the soluble 
enzyme preparation made from nuclei were extensi- 
vely inhibited by cw-amanitin, whereas the polymerase 
activity of the nucleolar enzyme was only slightly 
affected by the toxin under the same conditions. 
The resistance to o-amanitin or to rifampicin of 
polymerases of different origins, mammalian, ciliata 
(tetrahymena) and yeast can be used to get insight 
into similarities or dissimilarities of these enzymes. 
It was found that the tetrahymena [23] and the 
yeast [24] enzymes resemble mammalian RNA-poly- 
merase in sensitivity to a-amanitin and resistance to 
rifampicin. 
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4. Ribosomes 
4.1. Peptide bond formation and translocation 
Ribosomes have two sites for functional binding 
of aminoacyl tRNA. These sites have been called 
acceptor and donor sites. The donor site (D) is the 
site where the amino acid of peptidyl tRNA is do- 
nated to the incoming aminoacyl tRNA. The site 
where the incoming aminoacyl tRNA is bound, is 
called acceptor site (A). Aminoacyl tRNA can be 
replaced by the antibiotic puromycin. 
Kaji et al. [25,26] have developed an assay which 
allows one to study partial reactions of protein syn- 
thesis such as peptide bond formation and translo- 
cation of peptidyl tRNA. Using this assay it is 
possible to discriminate between antibiotics acting 
on peptide bond formation or translocation. When 
the complex of r4C-Phe-tRNA, ribosomes and poly 
U is prepared in the presence of low Mg2+ concentra- 
tions, the tRNA is preferentially bound to the donor 
site, while at higher Mg2+ concentrations about equal 
distribution of r4C-Phe-tRNA to both donor and 
acceptor sites was observed. At low concentrations 
of Mg2+ 80% of the r4C-Phe-tRNA interacts imme- 
diately with puromycin; at high Mg2+ concentra- 
tion a peptide bond must first be formed between 
the two phenylalanine residues. In a second step 
the newly formed peptidyl tRNA must be translo 
cated by a translocase and GTP. Using these two 
different experimental conditions, it was possible 
to distinguish between the following antibiotics by 
their effects on peptide bond formation and trans- 
location. 
Fusidic acid (X), elythromycin (XI), chloramphe- 
nicol (XII), cycloheximide (XIII) and Zincomycin 
(XIV): Fusidic acid was found to be inhibitory to 
the puromycin (XV) reaction only under conditions 
which involve translocation and peptide bond for- 
mation. Erythromycin like fusidic acid specifically 
inhibits translocation. Cycloheximide affects trans- 
location like fusidic acid [27] . Chloramphenicol 
was suggested to be a specific inhibitor of peptide 
bond formation. As expected, chloramphenicol inhi- 
bits the puromycin reaction under both conditions 
to the same extent. Lincomycin behaves like chlor- 
amphenicol and, therefore, inhibits peptide bond 
formation. 
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4.2. Ribosomalproteins 
Recent work from several aboratories has shown 
that there are about 20 different proteins in the 30 
S and 34 proteins in the 50 S ribosomal subunit. 
For review see Traut et al. [28]. Very little is 
known up to now about the function of the ribo- 
somal proteins, thus it is impossible to distinguish 
the different proteins by their function. Therefore, 
antibiotics which interact specifically with riboso- 
ma1 proteins will become most valuable to get in- 
sight into the structural and functional relationship 
of ribosomal proteins. 
Streptomycin (XVI): The first step forward in 
this field was made by Nomura’s group, who iden- 
tified the 30 S ribosomal protein controlled by the 
streptomycin-resistant locus in E. coli. The ribo- 
somal proteins from both streptomycin-resistant 
and streptomycin-sensitive strains were fractionated. 
Reconstitutions were performed by combining 
fractions from the streptomycin-sensitive strain and 
mixing them with 16 S RNA under standard con- 
ditions for reconstitution. The streptomycin sensi- 
tivity of the resultant particle was assayed. It was 
found that a definite protein called Pm is responsible 
for the streptomycin phenotype [29] . This Pro pro- 
tein seems to be involved as a control factor in the 
specificity of codon recognition [30]. 
Pactamycin (XVII), kanamycin (XVIII), neomycin 
(XIX), bryamycin, oleandomycin (XIa), elythro- 
mycin and lincomycin can probably be used as 
markers for different ribosomal proteins and thus 
may help to elucidate the functional role of these 
proteins. This conclusion is based on the results of 
Harford and Sueoka [3 1 ] who have mapped resis- 
tance loci on the genome of Bacillus su btilis (W 128) 
for these inhibitors of protein synthesis. Since dif- 
ferent loci for each antibiotic have been obtained 
one should expect specific binding of the inhibitors 
to certain ribosomal proteins. 
4.3. Cytoplasmic and mitochondtial ribosomes 
Another fruitful and promising field opened when 
it became evident that yeast and eucaryotic systems 
contain two different types of ribosomes, mitochon- 
drial and cytoplasmic ribosomes, which respond dif- 
ferently to certain antibiotics. In yeast, for example, 
the function of cytoplasmic ribosomes can be totally 
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inhibited by cycloheximide whereas this inhibitor 
does not affect mitochondrial ribosomes. On the 
other hand, chloramphenicol does not prevent 
cytoplasmic protein synthesis, but inhibits mito- 
chondrial ribosomes specifically. Both inhibitors 
in combination have been used to investigate the 
synthesis of mitochondrial proteins in wild type 
yeast and in the respiration-deficient petite mutant 
under anaerobic conditions and during adaptation 
to oxygen [32,33]. 
Promitochondria occur in wild type yeast and 
in the respiratory deficient mutant. Under anaerobic 
conditions, when cytoplasmic protein synthesis was 
totally blocked by cycloheximide, promitochondria 
of the wild type exhibit a chloramphenicol-sensitive 
protein synthesizing system., whereas the petite 
mutants failed to show any promitochondrial pro- 
tein synthesis. During adaptation to oxygen, mito- 
chondria arise via the differentiation of promitochon- 
dria, in both the wild type strain and the petite mu- 
tants. The mitochondria of the wild type strain 
differ from the mitochondria of the petite mutants. 
The mutants lack ribosomal RNA and are unable to 
synthesize protein. This in vivo technique establishes 
conclusively that the defect of the mutant mito- 
chondria is not a consequence of their respiration 
deficiency or their increased lability. 
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Appendix 
(I) Actinomycin Cl (D). L-Thr, L-threonine; D-Val, D-ualine; 
L-Pro, L-probe; Sar, sarcosine; L-N-MeVaI, L-Wmethylvaline. 
(III) Daunomycin. 
(II) Ethidium bromide. 
Y 
CHI 
wt+% OH 
OCH, 
(IV) Nogalamycin. 
(V) Chromomycin A+ 
Me 
July 1971 
(VI) Mithramycin. 
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(VII) Irehdiamine A. 
T- 
c!H -co-Mi- 
F 
H-CD-NH-W 
-Y 
d --~-NH-C~-~!H-~~I~-CH+!H 
(VIII) Rifampicin. 
(IX) or_Amanitti. (X) Fusidic acid. 
(XI) Erythromycin C. (aa) Oleandomycin. 
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D(-) Threo isomer (Chloramphenicol) 
L(+) Erythro isomer 
D(-) Erythro isomer 
L(+) Threo isomer 
(XII) Chloramphenicol and its stereoisomers. 
(XV) Puromycin. (XVI) Streptomycin 
“6. 
(XII) Cycloheximide. 
(XIV) Lincomycin. 
(XVII) Pactamycin. 
(XVIII) Kanamycin A. (XIX) Neomycin B. 
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